Infectious diseases Flashcards
Conditions caused by GAS (strep pyogenes)
Pharyngitis
Retropharyngeal abscess
Scarlet fever
Impetigo, erysipelas, cellulitis (inc perianal)
Strep TSS
Rheumatic fever
APSG
Describe scarlet fever rash
- Fine, diffuse “sandpaper” rash - appears 24-48 hrs into illness (after 1st fever) but can be first sign
- Begins on neck and upper chest, spreads to rest of trunk and extremities, spares palms and soles
- Prominent in flexor skin creases (Pastia lines [from capillary rupture] - pathognomonic for scarlet fever)
- Lasts approx 1 week then fades with desquamation of trunk, hands and feet
Features of scarlet fever
- Due to GAS pyrogenic exotoxin
- Pharyngitis, lymphadenopathy, fever
- Sandpaper rash, appears 1-2 days post onset of fever
- Pastia’s lines
- Strawberry tongue
- Circumoral pallor
- Desquamation of trunk, hands and feet with fading of rash (~1 week after onset)
- Abdo pain, myalgia, malaise
What systemic complication is associated with impetigo? (GAS)
Post strep GN (from M serotypes 49, 55, 57,59)
NOT rheumatic fever
CMV (HHV-5) transmission
Urine, resp secretions, blood
Vertically - in utero by transplacental passage, passage through infected genital tract, postnatally via breast milk (or donor milk)
CMV cytomegalic inclusion disease signs
IUGR
Jaundice, hepatosplenomegaly
Thrombocytopaenia/anaemia
Blueberry muffin rash (also in rubella)
Microcephaly, cerebral atrophy
Chorioretinitis
SNHL
Lethargy, hypotonia, seizures
Periventricular intracebral calcifications (CMV CircuMVents the ventricles)
CMV - SNHL stats
10% asymptomatic children (1/3 if symptomatic) will have progressive SNHL +/- neurodisability (also seizures and CP)
Eye signs CMV v rubella
CMV - chorioretinitis
Rubella - cataracts
Risk period of CMV infection in pregnancy
Early in pregnancy - transmission rate 30-50%
Diagnosis CMV
Urine CMV culture/PCR (and other sites) - must be within 2-4 wks to be “congenital”
Infant blood for CMV PCR
Paired maternal and infant serology
+ neuroimaging, opthal, audiology
MRI findings of CMV
Ventriculomegaly (hydrocephalus)
Periventricular calcifications
CMV v toxoplamosis MRI
CMV - microcephaly, ventriculomegaly, periventricular calcifications, lenticulostriate changes
Toxoplasmosis - hyrocephalus, diffuse cerebral calcifications
Congenital CMV treatment
Oral valganciclovir if <28 days AND moderate symptomatic disease (or IV ganciclovir if poor oral absorption)
Must treat for 6 mths
Risk of neutropaenia
TORCH
Toxoplasmosis
Other - syphilis, VSV, parvovirus, enteroviruses, Zika, GBS
Rubella
CMV
HSV
Neonatal HSV - risk of transmission
High if primary infection og genital herpes near the time of delivery
Low if hx of recurrent herpes
60-80% of pregnant F with HSV + babies have no prior clinical hx of HSV sx
Neonatal HSV presentation
45% - skin, eyes, mouth (SEM) - present in 1st 1-2 wks (sx = vesicular lesions, conjunctivitis, keratitis, chorioretinitis)
30% CNS only - present in 2nd-3rd week (sx = irritability, sz, poor feeding, lethargy - haemorrhagic CSF common with HSV)
25% disseminated - present in 1st 1-2 wks (sx = liver, lung, heart, kidney, CNS). Fatal in 50% cases
Neonatal HSV workup
HSV culture of mth, nasopharynx, eyes, anus
HSV culture and PCR of skin and mucosal lesions
HSV PCR of blood and CSF
LFTs
CXR
Opthal
Neuroimaging - MRI
Neonatal HSV treatment
Skin, eyes, mouth (SEM) - IV acyclovir 14 days
CNS or disseminated - IV acyclovir min 21 days + 6 mths PO acyclovir suppressive therapy
Hep B - chronic infection and complications rate of perinatal infections
90% become chronically infected if contract perinatally
25% develop cirrhosis and/or liver cancer in adult life
Maternal hep B Ag status - risk of transmission
Hep B - prevention of maternal transmission
1) Universal screening - if high initial, test viral load
2) Infants born to HbsAg pos Mo -> Hep B vaccin and HBIG within 12 hrs of birth
3) 3 further doses of Hep B vaccine as per immunisation schedule
4) Infant testing at > 9 mths to monitor surface antibody and rule out infection (ie HBsAg neg)
5) +/- tenofovir anti-viral Rx in Mo
Parvovirus B19 - complication of neonatal infection
Fetal anaemia, cardiac failure, hydrops
Treatment for parvovirus B19
No intervention available to prevent infection
Test fetus -> if positive, intrauterine transfusion to prevent foetal anaemia/hydrops
Monitor for anaemia postnatally
Presentation of neonatal parechovirus
Sepsis features - high fever, tachycardia, irritability, mottling, poor perfusion
Other - mottled red rash (erythrodermic), abdo distension, oedema, hepatitis
Presentation more severe than appears from bloods
Test via PCR (throat/rectal swabs)
Nb HPeVs-3 outbreak 2015
Condition?
Parechovirus - septic, oedematous, mottled red rash, abdominal distension
Congenital rubella - antenatal risk period
Highest risk if maternal infection pre-conception or 1st trimester (up to 50%)
Congenital rubella syndrome - classic triad
SNHL (58%)
Eyes - cataracts, retinopathy, micropthalmia (43%)
Cardiac - PA stenosis, PDA
Antenatal risk of VSV
Highest between 8 and 20 wks gestation - more likely to have birth defects then
VSV - clinical signs
Cicatricial skin scarring (dermatomal distribution)
Limb hypoplasia
Microcephaly, cortical atrophy
Seizures
Cataracts
Chorioretinitis, micropthalmia, nystagmus
Neuro defects
VSV treatment for exposed pregnant women
If immune compromised -> give VZ IG ASAP - until 10 days post exposure
If not available - give IVIG
Do NOT give VSV vaccine if pregnant (live vaccine)
Treatment for neonatal exposure to maternal VSV
> 7 days before delivery - no treatment
<7 days before ->2 days post - give VZIG
If under 28 weeks - give VZIG (maternal antibodies would not have crossed placenta)
Toxoplasmosis - how caught + presentation
Risk factors - ats, kitty litter, gardening, eating unwashed/raw vegetables or undercooked meat
Self limited non-specific illness in immune competent hosts
Crosses placenta 4-8 wks after maternal infection
Toxoplasmosis - risk of maternal infection
1st trimester - low risk (10-15%) but complications +++
1nd trimester - 30%
3rd trimester - 60%, but low complication rate